J&J Asks Pa. Court To Keep Risperdal Docs Under Seal
Law360, Philadelphia (December 2, 2013, 5:18 PM EST) -- Johnson & Johnson told a Pennsylvania state judge that counsel for plaintiffs in a slew of product liability suits over the drug Risperdal were improperly seeking to publicly release a series of clinical studies that were kept under seal by a 2011 court order.
The company and its subsidiary Janssen Pharmaceuticals Inc. argued in filing last Tuesday that the documents in question were neither filed with the court nor deemed public records, and thus are exempt from public access.
"These materials are generated for scientists, researchers and regulatory authorities — not the general public. Simply stated, no legitimate purpose would be...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!